Personal information

Emails & domains

Verified email addresses

Verified email domains

Activities

Collapse all

Works (5)

A High-Throughput Immune-Oncology Screen Identifies Immunostimulatory Properties of Cytotoxic Chemotherapy Agents in TNBC

Cancers
2024-12-05 | Journal article
DOI: 10.3390/cancers16234075
Contributors: Kennady K. Bullock; Thomas Hasaka; Emily Days; Joshua A. Bauer; Patricia A. Ward; Ann Richmond
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

A High-Throughput Immune-Oncology Screen Identifies Immunostimulatory Properties of Cytotoxic Chemotherapy Agents in TNBC

2024-11-08 | Preprint
DOI: 10.20944/preprints202411.0535.v1
Contributors: Kennady K Bullock; Thomas P Hasaka; Emily Days; Joshua A Bauer; Patricia A Ward; Ann Richmond
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer

Cancers
2024-06-11 | Journal article
DOI: 10.3390/cancers16122189
Contributors: Kennady K. Bullock; Ann Richmond
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC

Cancer Letters
2024-04 | Journal article
DOI: 10.1016/j.canlet.2024.216681
Contributors: Kennady K. Bullock; Rebecca Shattuck-Brandt; Carly Scalise; Weifeng Luo; Sheau-Chiann Chen; Nabil Saleh; Paula I. Gonzalez-Ericsson; Guadalupe Garcia; Melinda E. Sanders; Gregory D. Ayers et al.
Source: check_circle
Crossref

Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy

Cancers
2021-12-15 | Journal article
DOI: 10.3390/cancers13246293
Contributors: Kennady Bullock; Ann Richmond
Source: check_circle
Crossref
grade
Preferred source (of 2)‎
How many people are using ORCID?